Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
Am J Hematol
.
2022 Aug;97(8):E296-E298.
doi: 10.1002/ajh.26618.
Epub 2022 Jun 9.
Authors
Carlo Gambacorti-Passerini
1
2
,
Franck Emmanuel Nicolini
3
,
Richard A Larson
4
,
Andrea Aroldi
1
2
,
Diletta Fontana
2
,
Rocco Piazza
1
2
,
Philipp le Coutre
5
,
Laura Antolini
2
,
Sarit Assouline
6
Affiliations
1
Hematology Division, ASST Monza, Monza, Italy.
2
University of Milano-Bicocca, Monza, Italy.
3
Hematology Department & INSERM U1052, Centre Léon Bérard, Lyon, France.
4
University of Chicago, Chicago, Illinois, USA.
5
Department of Hematology, Oncology, and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
6
Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
PMID:
35604243
PMCID:
PMC9543833
DOI:
10.1002/ajh.26618
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Protein Kinase Inhibitors / adverse effects
Substances
Protein Kinase Inhibitors